INmune Bio (NASDAQ:INMB – Get Free Report) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.2067) per share and revenue of $1.1550 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.
INmune Bio (NASDAQ:INMB – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04.
INmune Bio Stock Performance
Shares of NASDAQ INMB opened at $1.91 on Wednesday. INmune Bio has a 52-week low of $1.09 and a 52-week high of $2.85. The stock has a market cap of $50.77 million, a P/E ratio of -1.14 and a beta of 0.97. The firm has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.47.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on INmune Bio
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of INMB. Intech Investment Management LLC acquired a new stake in shares of INmune Bio during the second quarter worth $26,000. Squarepoint Ops LLC acquired a new position in INmune Bio in the 3rd quarter worth $30,000. Quadrature Capital Ltd bought a new position in INmune Bio during the 4th quarter worth about $26,000. Jane Street Group LLC bought a new position in INmune Bio during the 1st quarter worth about $142,000. Finally, Rhumbline Advisers raised its stake in shares of INmune Bio by 14.4% in the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after purchasing an additional 2,409 shares during the period. Institutional investors own 12.72% of the company’s stock.
About INmune Bio
INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.
The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.
Featured Stories
- Five stocks we like better than INmune Bio
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
